SE444764B - Antibakteriell komposition for medicinsk anvendning innehallande 6-/d(-)-alfa-(4-etyl-2,3-dioxo-1-piperazinylkarbonylamino)fenylacetamido/penicillansyra och ett beta-laktamasinhiberande penicillin eller cefalosporin - Google Patents
Antibakteriell komposition for medicinsk anvendning innehallande 6-/d(-)-alfa-(4-etyl-2,3-dioxo-1-piperazinylkarbonylamino)fenylacetamido/penicillansyra och ett beta-laktamasinhiberande penicillin eller cefalosporinInfo
- Publication number
- SE444764B SE444764B SE7806659A SE7806659A SE444764B SE 444764 B SE444764 B SE 444764B SE 7806659 A SE7806659 A SE 7806659A SE 7806659 A SE7806659 A SE 7806659A SE 444764 B SE444764 B SE 444764B
- Authority
- SE
- Sweden
- Prior art keywords
- sodium
- medical use
- acid
- dioxo
- ethyl
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims description 27
- 230000000844 anti-bacterial effect Effects 0.000 title claims description 26
- 230000000694 effects Effects 0.000 claims description 34
- 238000002347 injection Methods 0.000 claims description 19
- 239000007924 injection Substances 0.000 claims description 19
- MGFZNWDWOKASQZ-UMLIZJHQSA-M methicillin sodium Chemical compound [Na+].COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C([O-])=O)C(C)(C)S[C@@H]21 MGFZNWDWOKASQZ-UMLIZJHQSA-M 0.000 claims description 17
- 229940019826 methicillin sodium Drugs 0.000 claims description 17
- -1 2,6-dichlorophenyl Chemical group 0.000 claims description 16
- 108090000204 Dipeptidase 1 Proteins 0.000 claims description 14
- 229930182555 Penicillin Natural products 0.000 claims description 14
- 102000006635 beta-lactamase Human genes 0.000 claims description 14
- 230000002401 inhibitory effect Effects 0.000 claims description 12
- 150000003839 salts Chemical class 0.000 claims description 11
- 229930186147 Cephalosporin Natural products 0.000 claims description 10
- 229940124587 cephalosporin Drugs 0.000 claims description 10
- 150000001780 cephalosporins Chemical class 0.000 claims description 10
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 claims description 8
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 claims description 8
- 229940049954 penicillin Drugs 0.000 claims description 8
- SCLZRKVZRBKZCR-SLINCCQESA-M cloxacillin sodium Chemical compound [Na+].N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C([O-])=O)=O)C(=O)C1=C(C)ON=C1C1=CC=CC=C1Cl SCLZRKVZRBKZCR-SLINCCQESA-M 0.000 claims description 7
- 229960003026 cloxacillin sodium Drugs 0.000 claims description 7
- 229960003085 meticillin Drugs 0.000 claims description 6
- 239000002253 acid Substances 0.000 claims description 5
- 229960003326 cloxacillin Drugs 0.000 claims description 4
- LQOLIRLGBULYKD-JKIFEVAISA-N cloxacillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=CC=CC=C1Cl LQOLIRLGBULYKD-JKIFEVAISA-N 0.000 claims description 4
- RBKMMJSQKNKNEV-RITPCOANSA-N penicillanic acid Chemical compound OC(=O)[C@H]1C(C)(C)S[C@@H]2CC(=O)N21 RBKMMJSQKNKNEV-RITPCOANSA-N 0.000 claims description 4
- UIOFUWFRIANQPC-JKIFEVAISA-N Floxacillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=C(F)C=CC=C1Cl UIOFUWFRIANQPC-JKIFEVAISA-N 0.000 claims description 3
- 229960001585 dicloxacillin Drugs 0.000 claims description 3
- YFAGHNZHGGCZAX-JKIFEVAISA-N dicloxacillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=C(Cl)C=CC=C1Cl YFAGHNZHGGCZAX-JKIFEVAISA-N 0.000 claims description 3
- 229960004273 floxacillin Drugs 0.000 claims description 3
- 229960001019 oxacillin Drugs 0.000 claims description 2
- UWYHMGVUTGAWSP-JKIFEVAISA-N oxacillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=CC=CC=C1 UWYHMGVUTGAWSP-JKIFEVAISA-N 0.000 claims description 2
- LSBDFXRDZJMBSC-UHFFFAOYSA-N 2-phenylacetamide Chemical compound NC(=O)CC1=CC=CC=C1 LSBDFXRDZJMBSC-UHFFFAOYSA-N 0.000 claims 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims 2
- 159000000000 sodium salts Chemical class 0.000 claims 2
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 claims 1
- 239000003781 beta lactamase inhibitor Substances 0.000 claims 1
- 229940126813 beta-lactamase inhibitor Drugs 0.000 claims 1
- 235000014655 lactic acid Nutrition 0.000 claims 1
- 239000004310 lactic acid Substances 0.000 claims 1
- 229940126085 β‑Lactamase Inhibitor Drugs 0.000 claims 1
- 239000000243 solution Substances 0.000 description 21
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 16
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 16
- 239000011734 sodium Substances 0.000 description 16
- 229910052708 sodium Inorganic materials 0.000 description 16
- WCMIIGXFCMNQDS-IDYPWDAWSA-M piperacillin sodium Chemical compound [Na+].O=C1C(=O)N(CC)CCN1C(=O)N[C@H](C=1C=CC=CC=1)C(=O)N[C@@H]1C(=O)N2[C@@H](C([O-])=O)C(C)(C)S[C@@H]21 WCMIIGXFCMNQDS-IDYPWDAWSA-M 0.000 description 14
- 241000894006 Bacteria Species 0.000 description 10
- 239000011780 sodium chloride Substances 0.000 description 8
- 241000588724 Escherichia coli Species 0.000 description 7
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 7
- 150000002960 penicillins Chemical class 0.000 description 7
- 244000052616 bacterial pathogen Species 0.000 description 6
- 229940126062 Compound A Drugs 0.000 description 3
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 3
- 239000008055 phosphate buffer solution Substances 0.000 description 3
- 230000002195 synergetic effect Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 241000588747 Klebsiella pneumoniae Species 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 241000588769 Proteus <enterobacteria> Species 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 230000000747 cardiac effect Effects 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000009036 growth inhibition Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 229960004393 lidocaine hydrochloride Drugs 0.000 description 2
- YECIFGHRMFEPJK-UHFFFAOYSA-N lidocaine hydrochloride monohydrate Chemical compound O.[Cl-].CC[NH+](CC)CC(=O)NC1=C(C)C=CC=C1C YECIFGHRMFEPJK-UHFFFAOYSA-N 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- GNWUOVJNSFPWDD-XMZRARIVSA-M Cefoxitin sodium Chemical compound [Na+].N([C@]1(OC)C(N2C(=C(COC(N)=O)CS[C@@H]21)C([O-])=O)=O)C(=O)CC1=CC=CS1 GNWUOVJNSFPWDD-XMZRARIVSA-M 0.000 description 1
- BWLUMTFWVZZZND-UHFFFAOYSA-N Dibenzylamine Chemical compound C=1C=CC=CC=1CNCC1=CC=CC=C1 BWLUMTFWVZZZND-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 108010087702 Penicillinase Proteins 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229960002682 cefoxitin Drugs 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000012531 culture fluid Substances 0.000 description 1
- 229960004060 dicloxacillin sodium Drugs 0.000 description 1
- SIGZQNJITOWQEF-VICXVTCVSA-M dicloxacillin sodium monohydrate Chemical compound O.[Na+].N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C([O-])=O)=O)C(=O)C1=C(C)ON=C1C1=C(Cl)C=CC=C1Cl SIGZQNJITOWQEF-VICXVTCVSA-M 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000003978 infusion fluid Substances 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- ACTNHJDHMQSOGL-UHFFFAOYSA-N n',n'-dibenzylethane-1,2-diamine Chemical compound C=1C=CC=CC=1CN(CCN)CC1=CC=CC=C1 ACTNHJDHMQSOGL-UHFFFAOYSA-N 0.000 description 1
- 230000017066 negative regulation of growth Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229960003994 oxacillin sodium Drugs 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 229950009506 penicillinase Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- VDUVBBMAXXHEQP-ZTRPPZFVSA-M sodium;(2s,6r)-3,3-dimethyl-6-[(5-methyl-3-phenyl-1,2-oxazole-4-carbonyl)amino]-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate Chemical compound [Na+].N([C@@H]1C(N2[C@H](C(C)(C)SC21)C([O-])=O)=O)C(=O)C1=C(C)ON=C1C1=CC=CC=C1 VDUVBBMAXXHEQP-ZTRPPZFVSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001635 urinary tract Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
- A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
- A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP6670777A JPS542337A (en) | 1977-06-08 | 1977-06-08 | Bactericidal composition for medical use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| SE7806659L SE7806659L (sv) | 1978-12-09 |
| SE444764B true SE444764B (sv) | 1986-05-12 |
Family
ID=13323663
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SE7806659A SE444764B (sv) | 1977-06-08 | 1978-06-07 | Antibakteriell komposition for medicinsk anvendning innehallande 6-/d(-)-alfa-(4-etyl-2,3-dioxo-1-piperazinylkarbonylamino)fenylacetamido/penicillansyra och ett beta-laktamasinhiberande penicillin eller cefalosporin |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US4199566A (enExample) |
| JP (1) | JPS542337A (enExample) |
| BE (1) | BE867909A (enExample) |
| CH (1) | CH634991A5 (enExample) |
| DE (1) | DE2824610C2 (enExample) |
| FR (1) | FR2393578A1 (enExample) |
| GB (1) | GB2000966B (enExample) |
| IL (1) | IL54941A (enExample) |
| NL (1) | NL7806163A (enExample) |
| PH (1) | PH16702A (enExample) |
| SE (1) | SE444764B (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2102911C3 (de) * | 1971-01-22 | 1982-12-23 | Maschinenfabrik Fahr Ag Gottmadingen, 7702 Gottmadingen | Kreiselmähwerk |
| JPS542337A (en) * | 1977-06-08 | 1979-01-09 | Toyama Chem Co Ltd | Bactericidal composition for medical use |
| CA1209477A (en) * | 1981-03-26 | 1986-08-12 | Bruce E. Haeger | Composition of matter comprising a lyophilized preparation of a penicillin derivative |
| US4615701A (en) * | 1984-01-03 | 1986-10-07 | Woods Randall L | Intraocular lens and method of implantation thereof |
| JPH0426647Y2 (enExample) * | 1985-01-22 | 1992-06-26 | ||
| DE69019395D1 (de) | 1989-02-21 | 1995-06-22 | Banyu Pharma Co Ltd | Zusammensetzung gegen Mikroben. |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1272660A (en) * | 1969-12-24 | 1972-05-03 | Beecham Group Ltd | Therapeutic compositions |
| GB1405886A (en) * | 1971-11-01 | 1975-09-10 | Astra Laekemedel Ab | Synergistic compositions comprising penicillin and cephalosporin antibiotics |
| JPS50117910A (enExample) * | 1974-02-28 | 1975-09-16 | ||
| JPS542337A (en) * | 1977-06-08 | 1979-01-09 | Toyama Chem Co Ltd | Bactericidal composition for medical use |
-
1977
- 1977-06-08 JP JP6670777A patent/JPS542337A/ja active Granted
-
1978
- 1978-06-05 DE DE2824610A patent/DE2824610C2/de not_active Expired
- 1978-06-06 NL NL7806163A patent/NL7806163A/xx active Search and Examination
- 1978-06-06 US US05/913,105 patent/US4199566A/en not_active Expired - Lifetime
- 1978-06-07 PH PH21239A patent/PH16702A/en unknown
- 1978-06-07 FR FR787817016A patent/FR2393578A1/fr active Granted
- 1978-06-07 CH CH621078A patent/CH634991A5/de not_active IP Right Cessation
- 1978-06-07 SE SE7806659A patent/SE444764B/sv not_active IP Right Cessation
- 1978-06-07 BE BE188399A patent/BE867909A/xx not_active IP Right Cessation
- 1978-06-08 GB GB7826564A patent/GB2000966B/en not_active Expired
- 1978-06-16 IL IL54941A patent/IL54941A/xx unknown
-
1980
- 1980-01-17 US US06/113,065 patent/US4324783A/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| JPS542337A (en) | 1979-01-09 |
| DE2824610C2 (de) | 1982-04-22 |
| SE7806659L (sv) | 1978-12-09 |
| GB2000966A (en) | 1979-01-24 |
| BE867909A (fr) | 1978-12-07 |
| US4324783A (en) | 1982-04-13 |
| FR2393578A1 (fr) | 1979-01-05 |
| FR2393578B1 (enExample) | 1980-07-18 |
| NL7806163A (nl) | 1978-12-12 |
| PH16702A (en) | 1984-01-16 |
| GB2000966B (en) | 1982-02-10 |
| IL54941A (en) | 1981-12-31 |
| DE2824610A1 (de) | 1978-12-14 |
| CH634991A5 (de) | 1983-03-15 |
| US4199566A (en) | 1980-04-22 |
| JPS6137248B2 (enExample) | 1986-08-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Higashitani et al. | Inhibition of β-lactamases by tazobactam and in-vitro antibacterial activity of tazobactam combined with piperacillin | |
| Fainstein et al. | A randomized study of ceftazidime compared to ceftazidime and tobramycin for the treatment of infections in cancer patients | |
| Miller et al. | Cefoxitin, a semisynthetic cephamycin antibiotic: in vivo evaluation | |
| Washburn et al. | Efficacy of Ampicillin Plus β-Lactamase Inhibitor (CP-45,899) in Experimental Endocarditis Due to Staphylococcus aureus | |
| SE444764B (sv) | Antibakteriell komposition for medicinsk anvendning innehallande 6-/d(-)-alfa-(4-etyl-2,3-dioxo-1-piperazinylkarbonylamino)fenylacetamido/penicillansyra och ett beta-laktamasinhiberande penicillin eller cefalosporin | |
| Sabath et al. | Increasing the usefulness of antibiotics: Treatment of infections caused by gram‐negative bacilli | |
| Williams | Classification of cephalosporins | |
| Maugh | A New Wave of Antibiotics Builds: New β-lactams active against resistant organisms are about to flood the market, but some physicians and hospitals may drown | |
| US4428936A (en) | Antibacterial composition for medical use | |
| Verbist et al. | In vitro activity of Ro 13-9904, a new beta-lactamase-stable cephalosporin | |
| Aubert et al. | In-vitro activity of cephalosporins alone and combined with sulbactam against various strains of Acinetobacter baumannii with different antibiotic resistance profiles | |
| US5658887A (en) | Pharmaceutical formulations comprising a clavulanic acid salt and erithromycin derivatite | |
| EP0003618B1 (en) | Antibacterial composition and use thereof | |
| EP2124935B1 (en) | Antibacterial combination and its use | |
| CA1119098A (en) | Antibacterial composition for medical use | |
| Sanders | Azlocillin: a new broad spectrum penicillin | |
| Randolph et al. | Comparative bactericidal effect of ceforanide (BL-S 786) and five other cephalosporins in an in vitro pharmacokinetic model | |
| Counts et al. | Comparative in vitro activity of the new oral cephalosporin cefixime | |
| IE47856B1 (en) | Antibacterial composition for medical use | |
| Spurlock et al. | Antibiotics in the treatment of wounds | |
| Jia | The progress in study of fosfomycin | |
| Legakis et al. | In vitro activity of ticarcillin, carbenicillin and ampicillin against some Gram-negative bacilli | |
| Waldvogel | The Future of β-Lactam Antibiotics | |
| Karaman et al. | Antibacterial activity of novel prodrugs of amoxicillin and cephalexin | |
| US4092411A (en) | Antibacterial composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| NAL | Patent in force |
Ref document number: 7806659-4 Format of ref document f/p: F |
|
| NUG | Patent has lapsed |
Ref document number: 7806659-4 Format of ref document f/p: F |